Wellgistics Health, Inc. (NASDAQ:WGRX) announced a partnership with DataVault AI, Inc. (NASDAQ:DVLT) to embed quantum‑key encryption into its PharmacyChain™ blockchain platform. The upgrade, announced on January 12, 2026, adds a quantum‑safe cryptographic layer that protects pharmacy‑dispensing data against the threat of future quantum computers, positioning PharmacyChain™ as a more secure solution for independent pharmacies.
The integration leverages DataVault AI’s Information Data Exchange (IDE) and its edge‑network infrastructure to embed post‑quantum cryptographic algorithms directly into the blockchain’s transaction validation process. By doing so, Wellgistics aims to preserve data integrity, reduce fraud risk, and meet evolving regulatory expectations for data security in the highly regulated prescription‑drug supply chain. The move also deepens a relationship that began with a SaaS agreement in October 2025 and an exclusive license for smart‑contract patents in November 2025.
The U.S. prescription‑drug market is valued at $634 billion, while the global blockchain‑in‑healthcare market is projected to grow from $11 billion to $214 billion by 2030. Wellgistics’ network of more than 6,500 independent pharmacies gives it a sizable addressable base, and the quantum‑encryption upgrade could differentiate its platform in a crowded market where data security is a key competitive lever.
Wellgistics has faced ongoing financial challenges, with a history of losses and a declared going‑concern risk. The company’s recent earnings reports have highlighted weak profit margins and negative EBITDA, underscoring the need for new revenue streams. The quantum‑encryption partnership does not yet generate direct revenue, but it is positioned to support future monetization through PharmacyChain™ usage fees and potential revenue‑sharing arrangements with DataVault AI, as outlined in earlier agreements.
Pilot milestones for 2026 are phased: Q1 focuses on blockchain selection, Q2 on HIPAA‑compliant data transfers, Q3 on closing pilot contracts, and year‑end on marketing. Successful pilots will validate the technology’s scalability and could unlock new revenue opportunities as the company seeks to expand its platform beyond independent pharmacies.
Prashant Patel, president and interim CEO of Wellgistics, said the partnership is “a crucial step forward” in modernizing the U.S. prescription‑drug ecosystem, emphasizing the company’s commitment to staying ahead of emerging cybersecurity threats while navigating its current financial headwinds.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.